Last reviewed · How we verify
Magnetic Resonance Imaging with Contrast — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Magnetic Resonance Imaging with Contrast (Magnetic Resonance Imaging with Contrast) — Bristol-Myers Squibb.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Magnetic Resonance Imaging with Contrast TARGET | Magnetic Resonance Imaging with Contrast | Bristol-Myers Squibb | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Magnetic Resonance Imaging with Contrast CI watch — RSS
- Magnetic Resonance Imaging with Contrast CI watch — Atom
- Magnetic Resonance Imaging with Contrast CI watch — JSON
- Magnetic Resonance Imaging with Contrast alone — RSS
Cite this brief
Drug Landscape (2026). Magnetic Resonance Imaging with Contrast — Competitive Intelligence Brief. https://druglandscape.com/ci/magnetic-resonance-imaging-with-contrast. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab